Skeletal Muscle Inflammation, Oxidative Stress and DNA Repair in Age-Related Sarcopenia

Sarcopenia Clinical Trial

Official title:

Claude D. Pepper Older Americans Independence Center (OAIC); Skeletal Muscle Inflammation, Oxidative Stress and DNA Repair in Age-Related Sarcopenia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02116166
• Other study ID #: 201300790-N
• Secondary ID: 2P30AG028740
• Status: Completed
• First received: April 14, 2014
• Last updated: April 4, 2018
• Start date: May 2014
• Est. completion date: July 2016

Study information

• Verified date: April 2018
• Source: University of Florida
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this research study is to investigate how and why the loss of muscle mass occurs with aging. Tissue collected from young subjects will be compared to previously collected tissue from elderly subjects, as well as previously collected data on muscle function/mass to further investigate cellular and molecular pathways that have recently been shown to be important for the aging process in muscle. The Principal Investigator (PI) and the study team will look for specific proteins (called biomarkers) that can be present in the muscle tissue in various amounts in different individuals. This study will increase the investigators understanding of the processes of muscle atrophy (loss of mass) and functional loss at older age and will help to find new treatments and interventions aimed at improving the quality of life and independence of America's rapidly expanding elderly population.

Description:

For this project, we will continue to gain mechanistic insight into age-related muscle loss and to maximize the utility of the tissue we previously collected (Claude D. Pepper Older Americans Independence Center (OAIC); Skeletal muscle apoptosis and physical performance; Oxidative RNA/DNA damage and repair in aged human muscle (Developmental Study), IRB # 429-2005) and we will collect muscle tissue from additional young subjects. This project will specifically test whether inflammatory pathways and DNA repair mechanisms are altered and/or involved in the development of sarcopenia and the related decline in physical function observed in the elderly.

Aim 1. We will further determine the association of skeletal muscle mass and function with intramuscular mediators of inflammation. Focus will be on inflammatory proteins (e.g.,TNF, TNFR1, pIkBα, pIKKb, CCL2, ZIP14, ZnT2) and genes (e.g., IL-6, TNFa, IL11β, IL-8, CCL2, CCR2, NFkB p50, NFkB p65, ZIP14) and metals (e.g., copper, zinc, and iron). We hypothesize that the majority of these markers will be upregulated in muscle from older individuals when compared to young.

Aim 2. For the first time, we will determine the age related effect of DNA damage on pattern and dynamics of mRNA translation in human muscle tissue by genome wide analysis using "ribosome profiling." The recently developed deep-sequencing techniques of RNA-seq and "ribosome profiling" will be implemented on human muscle. This will allow us to explore on a genomic scale and at single-nucleotide resolution, the effect of age-related DNA damage on transcriptional fidelity and translational kinetics. Importantly, for the first time, these phenotype changes will be compared with genome mapping of DNA damage, a major factor driving mammalian aging. We hypothesize that older muscle has greater modification of translational patterns compared to young muscle.

Muscle tissue samples remaining following the completion of this research will be stored and used in the future to explore new avenues of research related to aging.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: July 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 35 Years

Eligibility

Inclusion Criteria:

• males and females aged 20-35.

• willing and able to give informed consent.

Exclusion Criteria:

• High physical activity level (i.e., the subject has spent greater than 300 minutes per week in the past 2 month performing structured physical activity, such as exercising at a gym and/or weight training)

• Active treatment for cancer or history of cancer in the past 3 years

• Congestive heart failure NYHA Class III or IV

• Previous stroke with upper and/or lower extremities involvement within the last 6 months

• Peripheral vascular disease Fontaine Class III/IV

• History of life-threatening cardiac arrhythmias, stroke, severe Parkinson's disease or severe neurological disorders likely to interfere with physical function

• Renal disease requiring dialysis

• Lung disease requiring steroids

• Lower extremity amputation

• Complicated diabetes

• Life-threatening illnesses with an estimated life expectancy less than 1 year

• Anticoagulant therapy (aspirin use is allowed, but participants will be asked to stop taking it 48 hours prior to muscle biopsy)

• Involved in active weight loss > 5 kg in prior 3 months

• Pregnancy (determined by a pregnancy test)

• Lidocaine allergy

Temporary exclusion criteria:

• Recent bacterial infection (< 2 weeks)

• Acute febrile illness in previous 2 months

• High blood pressure (i.e., BP = 160/90 mm Hg) at the visit (subject will be referred to his/her physician and reevaluated after appropriated therapy being instituted)

• Taking aspirin within 48 hours preceding biopsy

• Performing exercise 48 hours prior to the biopsy.

Related Conditions & MeSH terms

• Inflammation
• Myositis
• Sarcopenia

Locations

Country	Name	City	State
United States	University of Florida	Gainesville	Florida

Sponsors (2)

Lead Sponsor	Collaborator
University of Florida	National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor Necrosis Factor alpha (TNF-alpha)	Inflammation marker; measured in muscle biopsy specimens.	baseline
Primary	tumor-necrosis factor receptor-1 (TNFR1)	Inflammation marker; measured in muscle biopsy specimens.	baseline
Primary	Phospho-Inhibitory Subunit Of NF-KBa (pIkBa)	Inflammation marker; measured in muscle biopsy specimens.	baseline
Primary	Chemokine (C-C motif) ligand 2 (CCL2)	Inflammation marker; measured in muscle biopsy specimens.	baseline
Primary	zinc transporter (ZIP) 14	Inflammation marker; measured in muscle biopsy specimens.	baseline
Primary	Interleukin 6 (IL-6)	Inflammation marker; measured in muscle biopsy specimens.	baseline
Primary	Interleukin (IL) 11ß	Inflammation marker; measured in muscle biopsy specimens.	baseline
Primary	Interleukin 8 (IL-8)	Inflammation marker; measured in muscle biopsy specimens.	baseline
Primary	C-C chemokine receptor type 2 (CCR2)	Inflammation marker; measured in muscle biopsy specimens.	baseline
Primary	zinc transporter 14 (ZIP14)	Inflammation marker; measured in muscle biopsy specimens.	baseline
Primary	copper	metals; measured in muscle biopsy specimens.	baseline
Primary	zinc	metals; measured in muscle biopsy specimens.	baseline
Primary	iron	metals; measured in muscle biopsy specimens.	baseline
Primary	ribosome profiling	DNA damage on pattern and dynamics of mRNA translation in human muscle tissue; measured in muscle biopsy specimens.	baseline

External Links

•   University of Florida Claude D. Pepper Older Americans Independence Center (OAIC)